Marktanalyse - Endocrinology Market to 2018 - Advanced Injection Devices for Growth Hormone and Somatostatin will Improve Ease of Use for Patients

Endocrinology Market to 2018 - Advanced Injection Devices for Growth Hormone and Somatostatin will Improve Ease of Use for Patients


Summary


GBI Research, the leading business intelligence provider, has released its latest research 'Endocrinology Market to 2018-Advanced Injection Devices for Growth Hormone and Somatostatin will Improve Ease of Use for Patients”, which provides insights into the endocrine disease therapeutics market until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The report provides an in-depth analysis of the major endocrine markets including growth hormone deficiency market, acromegaly market, male Hypogonadism market and hypothyroidism market. The report also provides the share of generics in the global endocrinology as well as in each indication market. The report examines the global endocrine disorders treatment usage patterns. It provides the geographical distribution of growth hormone deficiency, acromegaly, male hypogonadism, hypothyroidism and markets across the US, the top five countries of Europe and Japan. The report also includes insights into the endocrinology Research and Development (R&D) product pipeline and explores the competitive landscape, including major players in the market. Finally, the report includes analysis on Mergers and Acquisitions (M&A) and licensing agreements that took place in the endocrinology market.

GBI Research’s analysis shows that the overall global endocrinology market for the four indications was valued at $6.0 billion in 2010. It grew from $4.0 billion in 2004 at a CAGR of 6.9%. The market is expected to witness series of patent expiries , generic erosion and possible launches of novel molecules. The market is expected to witness comparatively moderate growth with a CAGR of 8.0% between 2010 and 2018, and is estimated to reach $11.2 billion in 2018. Patent expiries of blockbuster drugs such as Sandostatin LAR, Norditropin will restrict the growth of the market. The rapid uptake of novel dosage forms and formulations of existing drugs will increase the number of patients on treatment. Increased awareness among the general population about rare endocrine disorders will lead to an increase in market size in the forecast period.


Scope

- Data and analysis on the endocrinology market in the leading geographies of the world — the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the endocrinology market from 2004 to 2010, with forecasts to 2018.
- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
- Share of the generics in the global endocrinology market and for the market of each indication covered in the report.
- Key drivers and restraints that had a significant impact on the market.
- The competitive landscape of the global market including top companies benchmarking. The key companies studied in this report are Pfizer, Abbott, Novartis and Eli Lilly.
- Key M&A activities and licensing agreements that took place in 2009 and 2011 in the endocrinology market.


Reasons to buy

- Align your product portfolio to the markets with high growth potential.
- Build effective strategies to launch their pipeline products by identifying potential geographies with strong growth.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Create a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.


Press Release:

GBI Research, the leading business intelligence provider, has released its latest research 'Endocrinology Market to 2018 - Advanced Injection Devices for Growth Hormone and Somatostatin will Improve Ease of Use for Patients”, which provides insights into endocrinology until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The report provides an in-depth analysis of the major diseases including growth hormone deficiency, acromegaly, male hypogonadism and hypothyroidism. The report also provides the share of generics in the global endocrinology market as well as in each indication market. The report examines the global treatment usage patterns for each major disease. It provides the geographical distribution of growth hormone deficiency, acromegaly, male hypogonadism and hypothyroidism market across the US, the top five countries of Europe and in Japan. The report also includes insights into the endocrine therapeutics Research and Development (R&D) product pipeline and explores the competitive landscape including major players in the endocrinology market. Finally, the report includes analysis on Mergers and Acquisitions (M&A) and licensing agreements that took place in the endocrinology market.

GBI Research analysis shows that the endocrinology market is one of the competitive therapeutic segments with strong growth potential. Expensive biological therapies used in the treatment of endocrine disorders, the launch of novel drugs and increased usage of easy to use improved formulations of biologics are set to drive the endocrinology market.

Global Endocrinology Market is Set to Show Moderate Growth in Near Future

GBI Research valued the global endocrinology market at $6 billion in 2010, a CAGR of 6.9% from 2004 to 2010. The market is estimated to reach $11.2 billion in 2018, indicating a CAGR of 8.0% during the period 2010-2018. The acceptability of newer formulations of existing drugs, increased use of easy to use prefilled injection devices and expected launches of novel drug molecules in major therapy areas will contribute to the growth in the endocrinology market in the forecast period.

Acromegaly and growth hormone deficiency are the two major revenue generating therapy areas in the endocrinology market. The patent expiries of recombinant human growth hormone drugs such as Pfizer’s Genotropin, Eli Lilly’s Humatrope and F. Hoffmann La Roche’s Nutropin have already paved way for the entry of biogenerics in the growth hormone deficiency market. Furthermore patent expires of Novartis’s acromegaly drug Sandostatin LAR (2014 in the US) and Novo Nordisk’s Norditropin (2015) in the forecast period will accentuate the biogeneric erosion in forecast period in the endocrinology market.

The expected growth in the endocrinology market in the forecast period will be contributed by the expected launches of few promising molecules such as PLB03002, Arimidex, Pasireotide and C2L. Arimidex is a novel drug whereas PLB03002 is an improved formulation of recombinant human growth hormone for the treatment of growth hormone deficiency. Pasireotide, is a novel somatostatin analogue with high receptor affinity, and C2L is an improved formulation of octreotide being developed for the treatment of acromegaly.

Top Four Companies Contribute over 50% of the Global Endocrinology Therapy Area Sales

In 2010, the global endocrinology market was valued at $6.0 billion, with over 50% of the revenue attributable to the endocrinology specific sales of the leading four pharmaceutical companies in the sector: Pfizer, Abbott, Novartis and Novo Nordisk. Pfizer dominated the endocrinology market, with its drugs Genotropin, Somavert and Levoxyl. Somavert and Levoxyl became part of Pfizer through the recent acquisitions of Pharmacia and King Pharmaceuticals, respectively. The share of Pfizer is expected to decrease in the near future as biosimilars of Genotropin which entered the market have been leading to decline in branded Genotropin sales. Abbott is the second largest player in the endocrinology market with 13% of market share contribute by its drugs Synthroid and Androgel 1%. Novartis constitutes 11% of the market share with its acromegaly drug, Sandostatin LAR. Sandostatin LAR lost its patent in 2010, except in the US where its patent exclusivity ends in 2014. The decline in sales of Sandostatin LAR in the forecast period is expected to be balanced by the launch of acromegaly drug Pasireotide, which is now in Phase III. Eli Lilly constitutes 6% of the global endocrinology market with its drugs Humatrope and Axiron. Humatrope, one of the competitor drugs in the growth hormone deficiency market, witnessed a decline in sales following its patent expiry in 2008. Axiron, underarm testosterone therapy entered in 2010 for the treatment of male hypogonadim. Eli Lilly’s market share in the endocrinology market is expected to rise if Axiron well in the market.

Advanced Formulations of Biological Products are Set to Dominate the Endocrinology Market

The endocrinology market is expected to witness the introduction of innovative and improved formulations and drugs utilizing novel drug delivery technology. Unlike the frequent injections involved in hormone replacement therapy, novel formulations will easily penetrate the market due to high patient compliance. Therefore major pharmaceutical companies are concentrating on developing new formulations and drug delivery routes to establish their presence in the endocrinology market.

Pipeline molecules suggest that R&D is also concentrated more on the development of new formulations of hormones for quick and easy delivery. The most promising pipeline molecules include the newer and better versions of hormones such as LB03002 (sustained release recombinant human growth hormone), C2L (improved formulation version of Sandostatin LAR) and Bio-T-Gel (testosterone gel).

Analysis of major strategic consolidations in the endocrinology market suggests that the licensing of drugs with improved formulation are going to dominate the market. Majority of licensing agreements are signed for novel formulations such as Octreotide SDI, (a needle-free novel drug delivery system for octreotide), C2L, Somatuline Autogel (depot formulation of lanreotide), Straint SR (sustained release formulation of testosterone), Tirosint (levothyroxine liquid in soft gelatin capsule) and Axiron (underarm testosterone lotion). The number of licensing deals for improved formulations is expected to grow in the future as these advanced products will create a highly competitive market.

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 6

1.2 List of Figures 7

2 Endocrinology Market to 2018 - Introduction 9

2.1 GBI Research Report Guidance 10

3 Endocrinology Market to 2018 - Market Overview 11

3.1 Introduction 11

3.2 Revenue Forecasts for the Global Endocrinology Market 12

3.2.1 Revenue 12

3.2.2 Annual Cost of Therapy 13

3.2.3 Treatment Usage Patterns 14

3.3 Global Endocrinology Market Drivers 16

3.3.1 Rapid Uptake of New Formulation Products and Improved Injection Devices 16

3.3.2 Maintenance of Market Exclusivity and Revenues of Blockbuster Drugs by Extending Patent Life through Novel Drug Delivery Technologies 16

3.4 Global Endocrinology Market Restraints 17

3.4.1 Patent Expiries of Major Blockbuster Drugs Including Sandostatin LAR and Norditropin 17

3.4.2 Low Treatment Adherence in Growth Hormone Deficiency and Acromegaly Patients 17

3.5 Generics Share in the Global Endocrinology Market 18

4 Endocrinology Market to 2018 - Geographical Landscape 19

4.1 Revenue Analysis by Country 19

4.2 The US 21

4.2.1 Revenue 21

4.2.2 Annual Cost of Therapy 22

4.2.3 Treatment Usage Patterns 23

4.3 Top Five Countries in Europe 25

4.3.1 Revenue 25

4.3.2 Revenue Analysis by Country 26

4.3.3 Annual Cost of Therapy 27

4.3.4 Treatment Usage Patterns 28

4.4 Japan 30

4.4.1 Revenue 30

4.4.2 Annual Cost of Therapy 31

4.4.3 Treatment Usage Patterns 32

5 Endocrinology Market to 2018 - Therapeutic Landscape 34

5.1 Growth Hormone Deficiency 34

5.1.1 Introduction 34

5.1.2 Treatment Flow Algorithm for Growth Hormone Deficiency 35

5.1.3 Revenue 36

5.1.4 Revenue Analysis by Country 37

5.1.5 Annual Cost of Therapy 39

5.1.6 Treatment Usage Patterns 40

5.2 Acromegaly 42

5.2.1 Introduction 42

5.2.2 Treatment Flow Algorithm for Acromegaly 43

5.2.3 Revenue 44

5.2.4 Revenue Analysis by Country 45

5.2.5 Annual Cost of Therapy 47

5.2.6 Treatment Usage Patterns 48

5.3 Male Hypogonadism 49

5.3.1 Introduction 49

5.3.2 Treatment Flow Algorithm for Male Hypogonadism 50

5.3.3 Revenue 51

5.3.4 Revenue Analysis by Country 52

5.3.5 Annual Cost of Therapy 54

5.3.6 Treatment Usage Patterns 55

5.4 Hypothyroidism 57

5.4.1 Introduction 57

5.4.2 Treatment Flow Algorithm for Hypothyroidism 58

5.4.3 Revenue 59

5.4.4 Revenue Analysis by Country 61

5.4.5 Annual Cost of Therapy 63

5.4.6 Treatment Usage Patterns 64

6 Endocrinology Market to 2018 - Competitive Landscape 66

6.1 Market Share Analysis 66

6.2 Competitive Profiling 67

6.2.1 Pfizer 67

6.2.2 Novartis 69

6.2.3 Abbott 70

6.2.4 Novo Nordisk 71

6.2.5 Eli Lilly 72

7 Endocrinology Market to 2018 - Pipeline Analysis 73

7.1 Introduction 73

7.1.1 Research and Development Pipeline - Endocrinology Disorders Market 73

7.1.2 Most Promising Pipeline Molecules 77

8 Endocrinology Market to 2018 - Strategic Consolidations 79

8.1 Overview 79

8.2 Deals by Type 79

8.2.1 Pfizer Acquires King Pharmaceuticals in February 2011 79

8.2.2 Ipsen Acquires Tercica in October 2008 79

8.3 R&D Licensing Agreements 80

8.3.1 Deals by Indication 80

8.3.2 Deals by Phase 81

8.3.3 Deals by Geography 82

8.3.4 Licensing Agreements for Drugs in Phase II and Phase III 82

8.3.5 Licensing Agreements for Approved Drugs 84

9 Endocrinology Market to 2018 - Appendix 86

9.1 Market Definitions 86

9.2 Abbreviations 86

9.3 Research Methodology 87

9.3.1 Coverage 87

9.3.2 Secondary Research 87

9.3.3 Primary Research 88

9.4 Therapeutic Landscape 88

9.4.2 Market Size by Geography 90

9.5 Geographical Landscape 91

9.6 Pipeline Analysis 91

9.7 Competitive Landscape 91

9.7.1 Expert Panel Validation 91

9.8 Contact Us 91

9.9 Disclaimer 92

9.10 Sources 92





1.1 List of Tables

Table 1: Endocrinology Market, Global, Revenue, $bn, 2004-2010 12

Table 2: Endocrinology Market, Global, Revenue Forecasts, $bn, 2010-2018 12

Table 3: Endocrinology Market, Global, Annual Cost of Therapy, $, 2004-2010 13

Table 4: Endocrinology Market, Global, Annual Cost of Therapy, $, 2010-2018 13

Table 5: Endocrinology Market, Global, Treatment Usage Patterns, Millions, 2004-2010 14

Table 6: Endocrinology Market, Global, Treatment Usage Patterns, Thousands, 2010-2018 15

Table 7: Endocrinology Market, Global, Revenue by Country, $m, 2004-2010 19

Table 8: Endocrinology Market, Global, Revenue Forecasts by Country, $m, 2010-2018 20

Table 9: Endocrinology Market, The US, Revenue, $m, 2004-2010 21

Table 10: Endocrinology Market, The US, Revenue Forecasts, $m, 2010-2018 21

Table 11: Endocrinology Market, The US, Annual Cost of Therapy, $, 2004-2010 22

Table 12: Endocrinology Market, The US, Annual Cost of Therapy, $, 2010-2018 22

Table 13: Endocrinology Market, The US, Treatment Usage Patterns, Millions, 2004-2010 23

Table 14: Endocrinology Market, The US, Treatment Usage Patterns, Millions, 2010-2018 23

Table 15: Endocrinology Market, Top Five Countries of Europe, Revenue, $m, 2004-2010 25

Table 16: Endocrinology Market, Top Five Countries of Europe, Revenue Forecasts, $m, 2010-2018 25

Table 17: Endocrinology Market, Top Five Countries of Europe, Revenue by Country, $m, 2004-2010 26

Table 18: Endocrinology Market, Top Five Countries of Europe, Revenue Forecasts by Country, $m, 2010-2018 26

Table 19: Endocrinology Market, Top Five Countries of Europe, Annual Cost of Therapy, $, 2004-2010 27

Table 20: Endocrinology Market, Top Five Countries of Europe, Annual Cost of Therapy, $, 2010-2018 28

Table 21: Endocrinology Market, Top Five Countries of Europe, Treatment Usage Patterns, Millions, 2004-2010 29

Table 22: Endocrinology Market, Top Five Countries of Europe, Treatment Usage Patterns, Millions, 2010-2018 29

Table 23: Endocrinology Market, Japan, Revenue, $m, 2004-2010 30

Table 24: Endocrinology Market, Japan, Revenue Forecasts, $m, 2010-2018 30

Table 25: Endocrinology Market, Japan, Annual Cost of Therapy, $, 2004-2010 31

Table 26: Endocrinology Market, Japan, Annual Cost of Therapy, $, 2010-2018 31

Table 27: Endocrinology Market, Japan, Treatment Usage Patterns, Millions, 2004-2010 32

Table 28: Endocrinology Market, Japan, Treatment Usage Patterns, Millions, 2010-2018 33

Table 29: Growth Hormone Deficiency Therapeutics Market, Global, Revenue, $bn, 2004-2010 36

Table 30: Growth Hormone Deficiency Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2018 36

Table 31: Growth Hormone Deficiency Therapeutics Market, Global, Revenue by Country, $m, 2004-2010 37

Table 32: Growth Hormone Deficiency Therapeutics Market, Global, Revenue by Country, $m, 2010-2018 38

Table 33: Growth Hormone Deficiency Therapeutics Market, Global, Annual Cost of Therapy, $, 2004-2010 39

Table 34: Growth Hormone Deficiency Therapeutics Market, Global, Annual Cost of Therapy, $, 2010-2018 39

Table 35: Endocrinology Market, Growth Hormone Deficiency Therapeutics Market, Global, Treatment Usage Patterns, Thousands, 2004-2010 40

Table 36: Growth Hormone Deficiency Therapeutics Market, Global, Treatment Usage Patterns, Thousands, 2010-2018 41

Table 37: Acromegaly Therapeutics Market, Global, Revenue, $m, 2004-2010 44

Table 38: Acromegaly Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2018 44

Table 39: Acromegaly Therapeutics Market, Global, Revenue by Country, $m, 2004-2010 45

Table 40: Acromegaly Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2010-2018 46

Table 41: Acromegaly Therapeutics Market, Global, Annual Cost of Therapy, $, 2004-2010 47

Table 42: Acromegaly Therapeutics Market, Global, Annual Cost of Therapy, $, 2010-2018 47

Table 43: Acromegaly Therapeutics Market, Global, Treatment Usage Patterns, Thousand, 2004-2010 48

Table 44: Acromegaly Therapeutics Market, Global, Treatment Usage Patterns, Thousand, 2010-2018 48

Table 45: Male Hypogonadism Therapeutics Market, Global, Revenue, $m, 2004-2010 51

Table 46: Male Hypogonadism Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2018 51

Table 47: Male Hypogonadism Therapeutics Market, Global, Revenue by Country, $m, 2004-2010 52

Table 48: Male Hypogonadism Therapeutics Market, Global, Revenue by Country, $m, 2010-2018 53

Table 49: Male Hypogonadism Therapeutics Market, Global, Annual Cost of Therapy, $, 2004-2010 54

Table 50: Male Hypogonadism Therapeutics Market, Global, Annual Cost of Therapy, $, 2010-2018 54

Table 51: Male Hypogonadism Therapeutics Market, Global, Treatment Usage Patterns, Millions, 2004-2010 55

Table 52: Male Hypogonadism Therapeutics Market, Global, Treatment Usage Patterns, Millions, 2010-2018 56

Table 53: Hypothyroidism Therapeutics Market, Global, Revenue, $m, 2004-2010 59

Table 54: Hypothyroidism Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2018 59

Table 55: Hypothyroidism Therapeutics Market, Global, Revenue by Country, $m, 2004-2010 61

Table 56: Hypothyroidism Therapeutics Market, Global, Revenue by Country, $m, 2010-2018 62

Table 57: Hypothyroidism Therapeutics Market, Global, Annual Cost of Therapy, $, 2004-2010 63

Table 58: Hypothyroidism Therapeutics Market, Global, Annual Cost of Therapy , $, 2010-2018 63

Table 59: Hypothyroidism Therapeutics Market, Global, Treatment Usage Patterns, Millions, 2004-2010 64

Table 60: Hypothyroidism Therapeutics Market, Global, Treatment Usage Patterns, Millions, 2010-2018 65

Table 61: Endocrinology Market, Global, R&D Pipeline by Phase and by Indication, 2011 75

Table 62: Endocrinology Market, Global, Licensing Agreements for Drugs in Phase II and Phase III, 2005-2011 82

Table 63: Endocrinology Market, Global, Licensing Agreements for Approved Drugs, 2005-2011 84





1.2 List of Figures

Figure 1: Endocrinology Market, Global, Drivers and Restraints, 2011 11

Figure 2: Endocrinology Market, Global, Revenue Forecasts, $bn, 2004-2018 12

Figure 3: Endocrinology Market, Global, Annual Cost of Therapy, $, 2004-2018 13

Figure 4: Endocrinology Market, Global, Treatment Usage Patterns, Millions, 2004-2018 14

Figure 5: Endocrinology Market, Global, Branded versus Generic Drugs (%), 2010 18

Figure 6: Endocrinology Market, Revenue Forecasts by Country, $m, 2004-2018 19

Figure 7: Endocrinology Market, The US, Revenue, $bn, 2004-2018 21

Figure 8: Endocrinology Market, The US, Annual Cost of Therapy, $, 2004-2018 22

Figure 9: Endocrinology Market, The US, Treatment Usage Patterns, Millions, 2004-2018 23

Figure 10: Endocrinology Market, Top Five Countries of Europe, Revenue Forecasts, $m, 2004-2018 25

Figure 11: Endocrinology Market, Top Five Countries of Europe, Revenue Forecasts by Country, $m, 2004-2018 26

Figure 12: Endocrinology Market, Top Five Countries of Europe, Annual Cost of Therapy, $, 2004-2018 27

Figure 13: Endocrinology Market, Top Five Countries of Europe, Treatment Usage Patterns, Millions, 2004-2018 28

Figure 14: Endocrinology Market, Japan, Revenue Forecasts, $m, 2004-2018 30

Figure 15: Endocrinology Market, Japan, Annual Cost of Therapy, $, 2004-2018 31

Figure 16: Endocrinology Market, Japan, Treatment Usage Patterns, Millions, 2004-2018 32

Figure 17: Growth Hormone Deficiency Therapeutics Market, Global, Treatment Flow Algorithm, 2011 35

Figure 18: Growth Hormone Deficiency Therapeutics Market, Global, Revenue Forecasts, $bn, 2004-2018 36

Figure 19: Growth Hormone Deficiency Therapeutics Market, Global, Revenue by Country, $m, 2004-2018 37

Figure 20: Growth Hormone Deficiency Therapeutics Market, Global, Annual Cost of Therapy, $, 2004-2018 39

Figure 21: Growth Hormone Deficiency Therapeutics Market, Global, Treatment Usage Patterns, Thousands, 2004-2018 40

Figure 22: Acromegaly Therapeutics Market, Global, Treatment Flow Algorithm, 2011 43

Figure 23: Acromegaly Therapeutics Market, Global, Revenue Forecasts, $m, 2004-2018 44

Figure 24: Acromegaly Therapeutics Market, Global, Revenue by Country, $m, 2004-2018 45

Figure 25: Acromegaly Therapeutics Market, Global, Annual Cost of Therapy, $, 2004-2018 47

Figure 26: Acromegaly Therapeutics Market, Global, Treatment Usage Patterns, 2004-2018 48

Figure 27: Male Hypogonadism Therapeutics Market, Global, Treatment Flow Algorithm, 2011 50

Figure 28: Male Hypogonadism Therapeutics Market, Global, Revenue Forecasts, $m, 2004-2018 51

Figure 29: Male Hypogonadism Therapeutics Market, Global, Revenue by Country, $m, 2004-2018 52

Figure 30: Male Hypogonadism Therapeutics Market, Global, Annual Cost of Therapy, $, 2004-2018 54

Figure 31: Male Hypogonadism Therapeutics Market, Global, Treatment Usage Patterns, Thousands, 2004-2018 55

Figure 32: Hypothyroidism Therapeutics Market, Global, Treatment Flow Algorithm, 2011 58

Figure 33: Hypothyroidism Therapeutics Market, Global, Revenue Forecasts, $m, 2004-2018 59

Figure 34: Hypothyroidism Therapeutics Market, Global, Revenue by Country, $m, 2004-2018 61

Figure 35: Hypothyroidism Therapeutics Market, Global, Annual Cost of Therapy, $, 2004-2018 63

Figure 36: Hypothyroidism Therapeutics Market, Global, Treatment Usage Patterns, Millions, 2004-2018 64

Figure 37: Endocrinology Market, Global, Market Share by Company, %, 2010 66

Figure 38: Endocrinology Market, Global, SWOT - Pfizer, 2011 68

Figure 39: Endocrinology Market, Global, SWOT - Novartis, 2011 69

Figure 40: Endocrinology Market, Global, SWOT - Abbott, 2011 70

Figure 41: Endocrinology Market, Global, SWOT - Novo Nordisk, 2011 71

Figure 42: Endocrinology Market, Global, SWOT - Eli Lilly, 2011 72

Figure 43: Endocrinology Market, Global, R&D Pipeline by Indication, %, 2011 73

Figure 44: Endocrinology Market, Global, R&D Pipeline by Phase, %, 2011 74

Figure 45: Endocrinology Market, Global, M&A Deals by Type, %, 2005-2011 79

Figure 46: Endocrinology Market, Global, Major Licensing Agreements By Indication (%), 2005-2011 80

Figure 47: Endocrinology Market, Global, Major Licensing Agreements By Phase (%), 2005-2011 81

Figure 48: Endocrinology Market, Global, Major Licensing Agreements By Geography, %, 2005-2011 82

Figure 49: GBI Research Market Forecasting Model 90

• Growth Hormone Deficiency – Pipeline Review, H1 2013
• Chronic Kidney Disease (Chronic Renal Failure) – Pipeline Review, H1 2013
• Growth Disorders – Pipeline Review, H1 2013
• Kidney Fibrosis – Pipeline Review, H1 2013
• Urinary Incontinence – Pipeline Review, H1 2013
• Global Endocrinology Drugs Market 2012-2016
• Inguinal Hernia Global Clinical Trials Review, H1, 2013
• End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) – Pipeline Review, H2 2012
• Microalbuminuria – Pipeline Review, H2 2012
• Nocturia – Pipeline Review, H2 2012
• Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012
• Hypoparathyroidism – Pipeline Review, H2 2012
• Proteinuria – Pipeline Review, H2 2012
• Thyroid Gland Disorders – Pipeline Review, H2 2012
• Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline Review, H2 2012
• Hypothyroidism Global Clinical Trials Review, H2, 2012
• Interstitial Cystitis (Painful Bladder Syndrome) – Pipeline Review, H2 2012
• Other Genito Urinary Disorders – Pipeline Review, H2 2012
• Urinary Retention Global Clinical Trials Review, H2, 2012
• Focal Segmental Glomerulosclerosis (FSGS) – Pipeline Review, H2 2012